Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
EnhancedTRAIL, Soluble (human) (rec.) Pack
590
CHF
CHF 590.00
In stock
AG-44B-0002-KI011 SetCHF 590.00
| Product Details | |
|---|---|
| Synonyms | Apo-2L; TNFSF 10; CD253 |
| Product Type | Set |
| Properties | |
| Application Set | Compound Screening |
| Specificity | Binds to human and mouse TRAIL receptors and human osteoprotegrin (OPG). |
| Crossreactivity |
Human Mouse |
| Kit Contains |
1 Set 2x10μg TRAIL, Soluble (human) (rec.) (Prod. No. AG-40B-0003) 3x50μg TNF Ligands Enhancer (Prod. No. AG-35B-0001) |
| Other Product Data |
Source/Host: Produced in E. coli. A FLAG®-tag is fused at the N-terminus of the extracellular domain of human TRAIL (aa 95-281). Concentration: TRAIL: 0.1mg/ml after reconstitution TNF Ligands Enhancer: 1mg/ml after reconstitution Purity: ≥95% (SDS-PAGE) Formulation: Lyophilized. Contains PBS. Endotoxin Content: TRAIL: <0.01EU/µg purified protein (LAL test; Lonza). TNF Ligands Enhancer: <0.01EU/µg purified protein (LAL test; Lonza). Reconstitution: TRAIL: reconstitute with 100µl sterile water. PBS containing at least 0.1% BSA should be used for further dilutions. TNF Ligands Enhancer: reconstitute each vial with 50µl sterile water. PBS containing at least 0.1% BSA should be used for further dilutions. |
| Shipping and Handling | |
| Shipping | BLUE ICE |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
After reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. |
| Use/Stability | Stable for at least 6 months after receipt when stored at -20°C. |
| Documents | |
| Manual | No |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
Induces apoptosis in a concentration range of 5-50ng/ml in the presence of 1μg/ml of TNF Ligands Enhancer (Prod. No. AG-35B-0001).
Product References
- Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan: M. Dejosez, et al.; Cell Death Differ. 7, 1127 (2000)
- Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2: C.A. Benedict et al.; J. Biol. Chem. 276, 3270 (2001)
- The anti-apoptotic protein BAG-3 is overexpressed in pancreatic cancer and induced by heat stress in pancreatic cancer cell lines: Q. Liao, et al.; FEBS Lett. 503, 151 (2001)
- Caspase-10 is an initiator caspase in death receptor signaling: J. Wang, et al.; PNAS 98, 13884 (2001)
- Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells: C. Xiao, et al.; J. Biol. Chem. 277, 25020 (2002)
- TRAIL and its receptors in the colonic epithelium: a putative role in the defense of viral infections: J. Strater, et al.; Gastroenterology 122, 659 (2002)
- TRAIL/Apo-2 ligand induces primary plasma cell apoptosis: J. Ursini-Siegel, et al.; J. Immunol. 169, 5505 (2002)
- Induction of TRAIL-mediated glioma cell death by human T cells: J. Dörr, et al.; J. Neuroimmunol. 122, 117 (2002)
- Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells: S. Lacour, et al.; Oncogene 22, 1807 (2003)
- Human mast cells undergo TRAIL-induced apoptosis: B. Berent-Maoz, et al.; J. Immunol. 176, 2272 (2006)
Related Products
